impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

One year in review

 

One year in review 2020: novelties in the treatment of rheumatoid arthritis

1, 2, 3, 4, 5, 6, 7

 

  1. Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Cona, Ferrara, Italy.
  2. Rheumatology Unit, Department of Medicine, University of Verona, Policlinico G. B. Rossi, Verona, Italy.
  3. Chair and Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  4. Rheumatology Division, Multispecialist Medical Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, and Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy.
  5. Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Cona, Ferrara, Italy.
  6. Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Cona, Ferrara; and Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy. scrcll@unife.it
  7. Department of Rheumatology, Leiden University Medical Centre, The Netherlands.

CER13321
2020 Vol.38, N°2
PI 0181, PF 0194
One year in review

Free to view
(click on article PDF icon to read the article)

PMID: 32213264 [PubMed]

Received: 14/03/2020
Accepted : 16/03/2020
In Press: 26/03/2020
Published: 26/03/2020

Abstract

Rheumatoid arthritis (RA) management is driven by evidence, and new 2019 EULAR recommendations help in refining the relevant place of different disease-modifying anti-rheumatic drugs (DMARDs) in treatment schedules. At present, new drugs are in phase of development, mainly Janus Kinase inhibitors (JAKis), however, specific treatment strategies seem to count more than individual DMARDs in terms of treatment responses, given the substantial lack of head-to-head comparisons between specific biological (b) and targeted synthetic (ts)DMARDs, and with the general perception of a similar efficacy profile across drugs. In this setting, when reliable biomarkers able to predict treatment responses are lacking, treatment decisions are mainly driven by specific clinical or individual factors, given the recognised role of comorbidities, treatment-specific side effects, patients’ preferences, and costs on drug choice. In this narrative review, the authors give their specific point of view on the management of RA, based on a critical revision of the literature published in 2019, focusing on relevant novelties and future research directions.

DOI: https://doi.org/10.55563/clinexprheumatol/n6zc67

Rheumatology Article